3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase NA
1
Phase 1/2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
338
Neoplasms, Plasma Cell
56
Precursor Cell Lymphoblastic Leukemia-Lymphoma
54
Recurrence
50
Lymphoma
48
Leukemia
39
Neoplasms
27
Lymphoma, Mantle-Cell
27
Burkitt Lymphoma
26
Lymphoma, Large B-Cell, Diffuse
23
Immunoglobulin Light-chain Amyloidosis
23
Lymphoma, Non-Hodgkin
22
Waldenstrom Macroglobulinemia
21
Lymphoma, Follicular
17
Leukemia, Lymphocytic, Chronic, B-Cell
16
Hodgkin Disease
14
Nausea
12
Lymphoma, Extranodal NK-T-Cell
12
Lymphoma, B-Cell, Marginal Zone
12
Vomiting
11
Smoldering Multiple Myeloma
11
Prostatic Neoplasms
11
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
11
Breast Neoplasms
11
Renal Insufficiency
10
Neoplasm Metastasis
9
Lymphoma, Large-Cell, Immunoblastic
9
Carcinoma, Non-Small-Cell Lung
9
Lung Neoplasms
8
Leukemia, Biphenotypic, Acute
7
Interventions
venetoclax
3
ibrutinib
3
fludarabine phosphate
3
pomalidomide
2
Whole-Body Irradiation
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
Dexamethasone
2
pembrolizumab
1
fludarabine
1
daratumumab
1
carmustine, poliferprosan 20 drug combination
1
acalabrutinib
1
Tacrolimus
1
Nivolumab
1
Melphalan
1
Etoposide
1
Cytarabine
1
Cyclosporins
1
Cyclosporine
1
Cyclophosphamide
1
Carmustine
1
Atorvastatin
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Chromosome 17 deletion
×
Dexamethasone
×
Clear all
NCT01745640
2026-02-05
IFM2010-02
University Hospital, Lille
Phase 2
Completed
63 enrolled
NCT04124497
2025-08-08
DPd
Fondazione EMN Italy Onlus
Phase 2
Active not recruiting
45 enrolled